These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 30011350)

  • 21. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
    Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
    J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.
    Wong RJ; Nguyen MT; Trinh HN; Chan C; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Torres S; Yang J; Liu B; Garcia RT; Bhuket T; Baden R; Levitt B; da Silveira E; Gish RG
    J Viral Hepat; 2017 Dec; 24(12):1089-1097. PubMed ID: 28581644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
    Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
    Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
    Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy.
    Zhang XX; Li MR; Xi HL; Cao Y; Zhang RW; Zhang Y; Xu XY
    Chin Med J (Engl); 2016 Apr; 129(8):929-35. PubMed ID: 27064037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
    Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.
    Tangkijvanich P; Chittmittraprap S; Poovorawan K; Limothai U; Khlaiphuengsin A; Chuaypen N; Wisedopas N; Poovorawan Y
    J Viral Hepat; 2016 Jun; 23(6):427-38. PubMed ID: 26387494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
    Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
    J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
    Liem KS; van Campenhout MJH; Xie Q; Brouwer WP; Chi H; Qi X; Chen L; Tabak F; Hansen BE; Janssen HLA
    Aliment Pharmacol Ther; 2019 Feb; 49(4):448-456. PubMed ID: 30689258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B.
    Shao J; Wei L; Wang H; Sun Y; Zhang LF; Li J; Dong JQ
    World J Gastroenterol; 2007 Apr; 13(14):2104-7. PubMed ID: 17465456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.